Abstract:About one third of patients with Non-Small Cell Lung Cancer (NSCLC) presents at diagnosis with localized or locally advanced disease amenable to curative surgical resection. Surgical operability refers to stage I to IIIA and selected stage IIIB NSCLC. One of the main challenges in the management of early-stage resectable NSCLC is the optimization of available therapeutic strategies to prevent local and distant disease relapse, thus improving survival outcomes. There is evidence supporting the clinical use of both adjuvant and neoadjuvant immunotherapy-based strategies for resected/resectable, stage IB-IIIA NSCLC. Available data from randomized phase III trials have led to the incorporation of several immune checkpoint blockers (ICBs) into the international guidelines for early-stage NSCLC. Preclinical rationale of targeting specific subsets of T-cells by acting early on immune checkpoint receptors (e.g., PD-(L)1 and CTLA-4) is strong. Recent evidence is in favor of the neoadjuvant approach alone or as a part of perioperative strategy, demonstrating survival benefit. Combining neoadjuvant chemotherapy and immunotherapy before surgery results in both pathologic complete response (pCR) and major pathologic response (MPR) improvement, and survival outcomes, with no major safety issues. In this review, we summarize the rationale behind neoadjuvant/perioperative immunotherapy strategies and, due to the clinical relevance of immunotherapy in resectable NSCLC, we provide current evidence of this cutting-edge approach among special populations including older adults, women, and oncogene addicted NSCLC. To conclude, we present future perspectives in the use of immunotherapy for operable NSCLC with a special focus on novel investigational combinations underway.

Catecholamines in sow graafian follicles at proestrus and at diestrus.

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Bromus species in winter wheat-population dynamics and competitiveness.

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Matrices with prescribed Ritz values

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress

Emerging Evidence from Landmark Clinical Trials on Perioperative Immunotherapy in Resectable Non-Small Cell Lung Cancer

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

New Immunotherapy and Lung Cancer

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review

Angiosarcoma complicating generalized lymphangiectasia.

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer

Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers